Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients (Q36505748)

14 August 2017

1 reference

title

Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients (English)

1 reference

14 August 2017

1 reference

11

Lionel Rostaing

1 reference

14 August 2017

Flavio Vincenti

1

1 reference

14 August 2017

Amado de Andrés

2

1 reference

14 August 2017

Thomas Becker

3

1 reference

14 August 2017

Gabriel Choukroun

4

1 reference

14 August 2017

Edward Cole

5

1 reference

14 August 2017

José M González-Posada

6

1 reference

14 August 2017

Mysore A Kumar

7

1 reference

14 August 2017

Richard Moore

8

1 reference

14 August 2017

Silvio Nadalin

9

1 reference

14 August 2017

Björn Nashan

10

1 reference

14 August 2017

Kazuhide Saito

12

1 reference

14 August 2017

Norio Yoshimura

13

1 reference

14 August 2017

1 June 2006

1 reference

14 August 2017

Transplant International

1 reference

14 August 2017

19

1 reference

14 August 2017

6

1 reference

14 August 2017

446-457

1 reference

Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Acquisition of HLA-DR and costimulatory molecules by T cells from allogeneic antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveillance biopsy: 1-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Calcineurin-free protocols with basiliximab induction allow patients included in "old to old" programs achieve standard kidney transplant function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Costimulation blockade with belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Basiliximab: a review of its use as induction therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Economic analysis of basiliximab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Cost-minimization study comparing Simulect vs. Thymoglobulin in renal transplant induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Guide to development of practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Lymphomas after solid organ transplantation: a collaborative transplant study report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

Economic Implications of the Use of Basiliximab in Addition to Triple Immunosuppressive Therapy in Renal Allograft Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2006.00321.X

10.1111/J.1432-2277.2006.00321.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference